Melanoma & Skin Cancer

Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.

Sapna Patel, MD, reviews several key studies across stages of melanoma and emerging targeted therapies for patients with BRAF mutations.

After receiving FDA feedback regarding supplemental assay validation information and comparability data for lifileucel in advanced melanoma, Iovance Biotherapeutics will address these comments and plans to complete its rolling biologics license application submission during the first quarter of 2023.

The FDA has granted an orphan drug designation to the highly specific HDAC6 inhibitor AVS100 for the treatment of patients with stage IIB to IV melanoma.

The combination of sotigalimab and pembrolizumab showed encouraging antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Future advances in melanoma and other skin cancers should focus on team-oriented care and increasingly informed treatment sequencing regarding the roles of immunotherapy, targeted therapy, and surgery.

Richard D. Carvajal, MD, discusses the prognostic factors of uveal melanoma that differentiate it from other subsets of melanoma.

The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.

Nikhil Khushalani, MD, comments on upcoming treatment advances he looks forward to for patients with BCC.

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

An expert provides a brief overview of basal cell carcinoma (BCC) and reviews currently available treatment options for patients with BCC.

Dr Khushalani discusses challenges faced when treating patients with cSCC and shares advice for fellow colleagues who treat patients with cSCC.

Dr Hanna defines basal cell carcinoma (BCC), reviews current treatment options and explains the role of cemiplimab for the treatment of advanced BCC.

Dr Hanna highlights investigational agents that are being studied for the treatment of advanced cSCC and discuss some unmet needs for cSCC.

Omid Hamid, MD, highlights the importance of evaluating PRAME×CD3 Immune-mobilizing T cell receptor against cancer for melanoma treatment, the key benefits provided to patients through improved disease control and circulating tumor DNA reduction, and the safety profile of the therapy.

Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.

Nikhil Khushalani, MD, comments on updated data evaluating the use of cemiplimab in the neoadjuvant setting for patients with cSCC.

Neil D. Gross, MD, FACS, discusses the current deficits in the treatment of patients with cutaneous squamous cell carcinoma in the curative setting and avenues for continued research generated by the primary analysis of the phase 2 trial examining neoadjuvant cemiplimab in this population.

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.

Immunotherapy and targeted therapy combinations containing BRAF and MEK inhibitors have carved out roles in different settings of melanoma, which has given clinicians different options for treatment sequencing.

Dr Hanna comments on updated efficacy and safety data of the EMPOWER-CSCC-1 trial that was recently discussed at the annual ESMO and ASCO 2022 meetings.

Glenn J Hanna, MD, provides a brief overview of cutaneous squamous cell carcinoma (cSCC), and discusses the currently available treatment options for patients with advanced cSCC.